KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.97

Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

Rikke Løvendahl Eefsen, Nicklas Juel Spindler, Susann Theile, Gina Al-Farra, Helle W Hendel, Torben Lorentzen, Gitte Fredberg Persson, Claus P Behrens, Inna Markova Chen, Kasper Madsen, Lisa Sengeløv, Inge Marie Svane, Henriette Lindberg, Per Kongsted, Dorte Lisbeth Nielsen

J Immunother Cancer 14(7) e014803

PMID42493213
PMCID-
DOI10.1136/jitc-2026-014803
发表日期2026-07-23
入排依据:仅有 Phase I/II 证据,未达到确证性随机试验标准。
摘要

摘要

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Treatment options for mCRPC typically include chemotherapy and androgen receptor pathway inhibitors. Immune checkpoint inhibitors (ICIs) have demonstrated a limited effect in mCRPC. We hypothesized that the addition of stereotactic body radiation therapy (SBRT) could enhance immune responses and improve treatment outcomes. METHODS: Patients with mCRPC who had received at least two prior lines of therapy were randomized 1:1 to receive SBRT with nivolumab and ipilimumab (arm A) or nivolumab and ipilimumab (arm B). The dual primary endpoints in the study were prostate-specific antigen (PSA) response rate and objective response rate (ORR). Secondary endpoints included overall survival (OS), PSA, radiologic progression-free survival, and toxicity. RESULTS: We enrolled 91 patients, and 81 patients received at least one treatment with ICIs and were eligible for evaluation of the efficacy and safety endpoints. Of the evaluable patient population, the confirmed PSA response rate was 21.6% (95% CI 9.8% to 38.2%) in arm A, and 20.5% (95% CI 9.8% to 35.3%) in arm B. ORR was 16.7% (95% CI 4.7% to 37.4%) and 22.2% (95% CI 10.1% to 39.2%) in arms A and B, respectively. Median OS was 10.2 months (95% CI 7.1 to 15.2) in arm A and 9.2 months (95% CI 7.1 to 14.4) in arm B. Treatment-related adverse events grade 3-4 were observed in 27 patients (33.3%). CONCLUSIONS: The addition of SBRT to nivolumab and ipilimumab did not improve outcomes; however, a fraction of the patients had a response to the treatment combination of nivolumab and ipilimumab. Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC. TRIAL REGISTRATION NUMBERS: European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。